MaaT Pharma Awaits EMA Review for Xervyteg® as 2025 Results Show Clinical Progress
Event summary
- MaaT Pharma reported a net loss of €31.1 million for 2025, up from €28.9 million in 2024, driven by increased R&D and SG&A expenses.
- The company received €10.5 million upfront from Clinigen for the license and distribution agreement for Xervyteg® (MaaT013), with potential milestone payments up to €18 million.
- Xervyteg® (MaaT013) is under EMA review, with a potential first-in-class approval in oncology anticipated in 2026.
- MaaT033's Phase 2b PHOEBUS trial timeline has been extended to Q4 2028 due to resource prioritization on Xervyteg®.
- The company's cash position increased to €24.9 million as of December 31, 2025, with an estimated runway until June 2026.
The big picture
MaaT Pharma's 2025 results highlight its focus on advancing Xervyteg® through the EMA review process, a critical milestone for the company's hemato-oncology portfolio. The strategic shift in resource allocation to prioritize Xervyteg® reflects the competitive dynamics in the microbiome-driven therapies space, where first-mover advantage is crucial. The company's ability to balance regulatory progress with financial sustainability will be key to its long-term success in a market characterized by high R&D costs and stringent regulatory requirements.
What we're watching
- Regulatory Milestones
- The pace at which the EMA review progresses for Xervyteg® will determine the timeline for potential commercialization and milestone payments.
- Pipeline Execution
- Whether MaaT Pharma can sustain the development of MaaT033 and MaaT034 while prioritizing Xervyteg® will impact its long-term growth potential.
- Financial Sustainability
- How the company plans to secure additional financing to support its development portfolio beyond the current cash runway.
Related topics